메뉴 건너뛰기




Volumn 1, Issue 1, 2012, Pages

Erratum: A mechanistic, model-based approach to safety assessment in clinical development (CPT: Pharmacometrics and Systems Pharmacology (2012) 1 (e13) DOI: 10.1038/psp.2012.14);A mechanistic, model-based approach to safety assessment in clinical development

Author keywords

[No Author keywords available]

Indexed keywords

PRAVASTATIN; SIMVASTATIN;

EID: 84875430515     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2012.22     Document Type: Erratum
Times cited : (34)

References (48)
  • 1
    • 77649234756 scopus 로고    scopus 로고
    • How to improve R&D productivity: The pharmaceutical industry's grand challenge
    • Paul, S.M. et al. How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203-214 (2010
    • (2010) Nat. Rev. Drug Discov , vol.9 , pp. 203-214
    • Paul, S.M.1
  • 2
    • 79955601786 scopus 로고    scopus 로고
    • Trial watch: Phase II failures: 2008-2010
    • Arrowsmith, J. Trial watch: Phase II failures: 2008-2010. Nat. Rev. Drug Discov. 10, 328- 329 (2011
    • (2011) Nat. Rev. Drug Discov , vol.10 , pp. 328-329
    • Arrowsmith, J.1
  • 4
    • 70449528780 scopus 로고    scopus 로고
    • In silico toxicology for the pharmaceutical sciences
    • Valerio, L.G. Jr. In silico toxicology for the pharmaceutical sciences. Toxicol. Appl. Pharmacol. 241, 356-370 (2009
    • (2009) Toxicol. Appl. Pharmacol , vol.241 , pp. 356-370
    • Valerio Jr., L.G.1
  • 5
    • 84862523209 scopus 로고    scopus 로고
    • Web tools for predictive toxicology model building
    • Jeliazkova, N. Web tools for predictive toxicology model building. Expert Opin. Drug Metab. Toxicol. 8, 791-801 (2012
    • (2012) Expert Opin. Drug Metab. Toxicol , vol.8 , pp. 791-801
    • Jeliazkova, N.1
  • 6
    • 79955745792 scopus 로고    scopus 로고
    • Impact of computational structure-based predictive toxicology in drug discovery
    • Mohan, C.G. Impact of computational structure-based predictive toxicology in drug discovery. Comb. Chem. High Throughput Screen. 14, 417-426 (2011
    • (2011) Comb. Chem. High Throughput Screen , vol.14 , pp. 417-426
    • Mohan, C.G.1
  • 7
    • 84865271285 scopus 로고    scopus 로고
    • Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results
    • Yoon, M., Campbell, J.L., Andersen, M.E. & Clewell, H.J. Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results. Crit. Rev. Toxicol. 42, 633-652 (2012
    • (2012) Crit. Rev. Toxicol , vol.42 , pp. 633-652
    • Yoon, M.1    Campbell, J.L.2    Andersen, M.E.3    Clewell, H.J.4
  • 8
    • 49949104757 scopus 로고    scopus 로고
    • SLCO1B1 variants and statin-induced myopathy-A genomewide study
    • Link, E. et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med. 359, 789-799 (2008
    • (2008) N. Engl. J. Med , vol.359 , pp. 789-799
    • Link, E.1
  • 9
    • 0014858473 scopus 로고
    • Generalized solution to linear, to compartment, open model for drug distribution
    • Bischoff, K.B. & Dedrick, R.L. Generalized solution to linear, to compartment, open model for drug distribution. J. Theor. Biol. 29, 63-68 (1970
    • (1970) J. Theor. Biol , vol.29 , pp. 63-68
    • Bischoff, K.B.1    Dedrick, R.L.2
  • 10
    • 58849107587 scopus 로고    scopus 로고
    • Meeting report: Moving upstream-evaluating adverse upstream end points for improved risk assessment and decision-making
    • Woodruff, T.J. et al. Meeting report: moving upstream-evaluating adverse upstream end points for improved risk assessment and decision-making. Environ. Health Perspect. 116, 1568-1575 (2008
    • (2008) Environ. Health Perspect , vol.116 , pp. 1568-1575
    • Woodruff, T.J.1
  • 11
    • 78649736009 scopus 로고    scopus 로고
    • PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals
    • Bois, F.Y., Jamei, M. & Clewell, H.J. PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. Toxicology 278, 256-267 (2010
    • (2010) Toxicology , vol.278 , pp. 256-267
    • Bois, F.Y.1    Jamei, M.2    Clewell, H.J.3
  • 12
    • 41949099850 scopus 로고    scopus 로고
    • Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: The first steps
    • Loizou, G. et al. Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: The first steps. Regul. Toxicol. Pharmacol. 50, 400-411 (2008
    • (2008) Regul. Toxicol. Pharmacol , vol.50 , pp. 400-411
    • Loizou, G.1
  • 13
    • 33748338819 scopus 로고    scopus 로고
    • From physicochemistry to absorption and distribution: Predictive mechanistic modelling and computational tools
    • Willmann, S., Lippert, J. & Schmitt, W. From physicochemistry to absorption and distribution: Predictive mechanistic modelling and computational tools. Expert Opin. Drug Metab. Toxicol. 1, 159-168 (2005
    • (2005) Expert Opin. Drug Metab. Toxicol , vol.1 , pp. 159-168
    • Willmann, S.1    Lippert, J.2    Schmitt, W.3
  • 14
    • 70450240777 scopus 로고    scopus 로고
    • Risk to the breast-fed neonate from codeine treatment to the mother: A quantitative mechanistic modeling study
    • Willmann, S., Edginton, A.N., Coboeken, K., Ahr, G. & Lippert, J. Risk to the breast-fed neonate from codeine treatment to the mother: A quantitative mechanistic modeling study. Clin. Pharmacol. Ther. 86, 634-643 (2009
    • (2009) Clin. Pharmacol. Ther , vol.86 , pp. 634-643
    • Willmann, S.1    Edginton, A.N.2    Coboeken, K.3    Ahr, G.4    Lippert, J.5
  • 15
    • 34447330544 scopus 로고    scopus 로고
    • Whole-body physiologically based pharmacokinetic models
    • Nestorov, I. Whole-body physiologically based pharmacokinetic models. Expert Opin. Drug Metab. Toxicol. 3, 235-249 (2007
    • (2007) Expert Opin. Drug Metab. Toxicol , vol.3 , pp. 235-249
    • Nestorov, I.1
  • 16
    • 0036075799 scopus 로고    scopus 로고
    • Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition
    • Poulin, P. & Theil, F.P. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J. Pharm. Sci. 91, 1358-1370 (2002
    • (2002) J. Pharm. Sci , vol.91 , pp. 1358-1370
    • Poulin, P.1    Theil, F.P.2
  • 18
    • 0029549676 scopus 로고
    • Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development
    • Charnick, S.B., Kawai, R., Nedelman, J.R., Lemaire, M., Niederberger, W. & Sato, H. Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development. J. Pharmacokinet. Biopharm. 23, 217-229 (1995
    • (1995) J. Pharmacokinet. Biopharm , vol.23 , pp. 217-229
    • Charnick, S.B.1    Kawai, R.2    Nedelman, J.R.3    Lemaire, M.4    Niederberger, W.5    Sato, H.6
  • 19
    • 13244280971 scopus 로고    scopus 로고
    • PK-Sim: A Physiologically Based Pharmacokinetic "whole-body" model
    • Willmann, S. et al. PK-Sim: A physiologically based pharmacokinetic "whole-body" model. Biosilico 1, 121-124 (2003
    • (2003) Biosilico , vol.1 , pp. 121-124
    • Willmann, S.1
  • 20
    • 3242778534 scopus 로고    scopus 로고
    • A physiological model for the estimation of the fraction dose absorbed in humans
    • Willmann, S., Schmitt, W., Keldenich, J., Lippert, J. & Dressman, J.B. A physiological model for the estimation of the fraction dose absorbed in humans. J. Med. Chem. 47, 4022-4031 (2004
    • (2004) J. Med. Chem , vol.47 , pp. 4022-4031
    • Willmann, S.1    Schmitt, W.2    Keldenich, J.3    Lippert, J.4    Dressman, J.B.5
  • 21
    • 84859883744 scopus 로고    scopus 로고
    • Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling
    • Meyer, M., Schneckener, S., Ludewig, B., Kuepfer, L. & Lippert, J. Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling. Drug Metab. Dispos. 40, 892-901 (2012
    • (2012) Drug Metab. Dispos , vol.40 , pp. 892-901
    • Meyer, M.1    Schneckener, S.2    Ludewig, B.3    Kuepfer, L.4    Lippert, J.5
  • 22
    • 9444256954 scopus 로고    scopus 로고
    • Toxicogenomics and systems toxicology: Aims and prospects
    • Waters, M.D. & Fostel, J.M. Toxicogenomics and systems toxicology: Aims and prospects. Nat. Rev. Genet. 5, 936-948 (2004
    • (2004) Nat. Rev. Genet , vol.5 , pp. 936-948
    • Waters, M.D.1    Fostel, J.M.2
  • 23
    • 76949094840 scopus 로고    scopus 로고
    • Risk factors and drug interactions predisposing to statin-induced myopathy: Implications for risk assessment, prevention and treatment
    • Chatzizisis, Y.S., Koskinas, K.C., Misirli, G., Vaklavas, C., Hatzitolios, A. & Giannoglou, G.D. Risk factors and drug interactions predisposing to statin-induced myopathy: Implications for risk assessment, prevention and treatment. Drug Saf. 33, 171-187 (2010
    • (2010) Drug Saf , vol.33 , pp. 171-187
    • Chatzizisis, Y.S.1    Koskinas, K.C.2    Misirli, G.3    Vaklavas, C.4    Hatzitolios, A.5    Giannoglou, G.D.6
  • 24
    • 70349739250 scopus 로고    scopus 로고
    • The SLCO1B1. 5 genetic variant is associated with statin-induced side effects
    • Voora, D. et al. The SLCO1B1. 5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol. 54, 1609-1616 (2009
    • (2009) J. Am. Coll. Cardiol , vol.54 , pp. 1609-1616
    • Voora, D.1
  • 25
    • 79953901458 scopus 로고    scopus 로고
    • Organic anion transporting polypeptide 1B1: A genetically polymorphic transporter of major importance for hepatic drug uptake
    • Niemi, M., Pasanen, M.K. & Neuvonen, P.J. Organic anion transporting polypeptide 1B1: A genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol. Rev. 63, 157-181 (2011
    • (2011) Pharmacol. Rev , vol.63 , pp. 157-181
    • Niemi, M.1    Pasanen, M.K.2    Neuvonen, P.J.3
  • 26
    • 72249115539 scopus 로고    scopus 로고
    • Does simvastatin cause more myotoxicity compared with other statins?
    • Backes, J.M., Howard, P.A., Ruisinger, J.F. & Moriarty, P.M. Does simvastatin cause more myotoxicity compared with other statins? Ann. Pharmacother. 43, 2012-2020 (2009
    • (2009) Ann. Pharmacother , vol.43 , pp. 2012-2020
    • Backes, J.M.1    Howard, P.A.2    Ruisinger, J.F.3    Moriarty, P.M.4
  • 27
    • 33749049136 scopus 로고    scopus 로고
    • SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin
    • Niemi, M., Pasanen, M.K. & Neuvonen, P.J. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin. Pharmacol. Ther. 80, 356-366 (2006
    • (2006) Clin. Pharmacol. Ther , vol.80 , pp. 356-366
    • Niemi, M.1    Pasanen, M.K.2    Neuvonen, P.J.3
  • 28
    • 33751096467 scopus 로고    scopus 로고
    • SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
    • Pasanen, M.K., Neuvonen, M., Neuvonen, P.J. & Niemi, M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics 16, 873-879 (2006
    • (2006) Pharmacogenet. Genomics , vol.16 , pp. 873-879
    • Pasanen, M.K.1    Neuvonen, M.2    Neuvonen, P.J.3    Niemi, M.4
  • 30
    • 0034495168 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of pravastatin: Mechanisms of pharmacokinetic events
    • Hatanaka, T. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin. Pharmacokinet. 39, 397-412 (2000
    • (2000) Clin. Pharmacokinet , vol.39 , pp. 397-412
    • Hatanaka, T.1
  • 31
    • 33846034416 scopus 로고    scopus 로고
    • Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans
    • Kivistö, K.T. & Niemi, M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm. Res. 24, 239-247 (2007
    • (2007) Pharm. Res , vol.24 , pp. 239-247
    • Kivistö, K.T.1    Niemi, M.2
  • 32
    • 2042469487 scopus 로고    scopus 로고
    • Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics
    • Mwinyi, J., Johne, A., Bauer, S., Roots, I. & Gerloff, T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther. 75, 415-421 (2004
    • (2004) Clin. Pharmacol. Ther , vol.75 , pp. 415-421
    • Mwinyi, J.1    Johne, A.2    Bauer, S.3    Roots, I.4    Gerloff, T.5
  • 33
    • 0025355830 scopus 로고
    • Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects
    • Singhvi, S.M., Pan, H.Y., Morrison, R.A. & Willard, D.A. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br. J. Clin. Pharmacol. 29, 239-243 (1990
    • (1990) Br. J. Clin. Pharmacol , vol.29 , pp. 239-243
    • Singhvi, S.M.1    Pan, H.Y.2    Morrison, R.A.3    Willard, D.A.4
  • 35
    • 0025077819 scopus 로고
    • Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia
    • Todd, P.A. & Goa, K.L. Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 40, 583-607 (1990
    • (1990) Drugs , vol.40 , pp. 583-607
    • Todd, P.A.1    Goa, K.L.2
  • 36
    • 72849141790 scopus 로고    scopus 로고
    • Transporter pharmacogenetics and statin toxicity
    • Niemi, M. Transporter pharmacogenetics and statin toxicity. Clin. Pharmacol. Ther. 87, 130-133 (2010
    • (2010) Clin. Pharmacol. Ther , vol.87 , pp. 130-133
    • Niemi, M.1
  • 37
    • 34948840834 scopus 로고    scopus 로고
    • Ensemble modeling for analysis of cell signaling dynamics
    • Kuepfer, L., Peter, M., Sauer, U. & Stelling, J. Ensemble modeling for analysis of cell signaling dynamics. Nat. Biotechnol. 25, 1001-1006 (2007
    • (2007) Nat. Biotechnol , vol.25 , pp. 1001-1006
    • Kuepfer, L.1    Peter, M.2    Sauer, U.3    Stelling, J.4
  • 38
    • 80054718671 scopus 로고    scopus 로고
    • A computational systems biology software platform for multiscale modeling and simulation: Integrating whole-body physiology, disease biology, and molecular reaction networks
    • Eissing, T. et al. A computational systems biology software platform for multiscale modeling and simulation: Integrating whole-body physiology, disease biology, and molecular reaction networks. Front. Physiol. 2, 4 (2011
    • (2011) Front. Physiol , vol.2 , Issue.4
    • Eissing, T.1
  • 39
    • 34249905607 scopus 로고    scopus 로고
    • Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs
    • Willmann, S. et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J. Pharmacokinet. Pharmacodyn. 34, 401-431 (2007
    • (2007) J. Pharmacokinet. Pharmacodyn , vol.34 , pp. 401-431
    • Willmann, S.1
  • 40
    • 41749102617 scopus 로고    scopus 로고
    • Association between risk of myopathy and cholesterol-lowering effect: A comparison of all statins
    • Kobayashi, M. et al. Association between risk of myopathy and cholesterol-lowering effect: A comparison of all statins. Life Sci. 82, 969-975 (2008
    • (2008) Life Sci , vol.82 , pp. 969-975
    • Kobayashi, M.1
  • 41
    • 0037031061 scopus 로고    scopus 로고
    • MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebocontrolled trial
    • Heart Protection Study Collaborative Group
    • Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebocontrolled trial. Lancet 360, 7-22, (2002
    • (2002) Lancet , vol.360 , pp. 7-22
  • 42
    • 33745031039 scopus 로고    scopus 로고
    • Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population
    • Pasanen, M.K., Backman, J.T., Neuvonen, P.J. & Niemi, M. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur. J. Clin. Pharmacol. 62, 409-415 (2006
    • (2006) Eur. J. Clin. Pharmacol , vol.62 , pp. 409-415
    • Pasanen, M.K.1    Backman, J.T.2    Neuvonen, P.J.3    Niemi, M.4
  • 43
    • 84857610609 scopus 로고    scopus 로고
    • Pharmacogenomics of codeine, morphine, and morphine- 6-glucuronide: Model-based analysis of the influence of CYP2D6 activity, UGT2B7 activity, renal impairment, and CYP3A4 inhibition
    • Eissing, T., Lippert, J. & Willmann, S. Pharmacogenomics of codeine, morphine, and morphine- 6-glucuronide: model-based analysis of the influence of CYP2D6 activity, UGT2B7 activity, renal impairment, and CYP3A4 inhibition. Mol. Diagn. Ther. 16, 43-53 (2012
    • (2012) Mol. Diagn. Ther , vol.16 , pp. 43-53
    • Eissing, T.1    Lippert, J.2    Willmann, S.3
  • 44
    • 83755196415 scopus 로고    scopus 로고
    • Statin-associated muscular and renal adverse events: Data mining of the public version of the FDA adverse event reporting system
    • Sakaeda, T., Kadoyama, K. & Okuno, Y. Statin-associated muscular and renal adverse events: Data mining of the public version of the FDA adverse event reporting system. PLoS ONE 6, e28124 (2011
    • (2011) PLoS ONE , vol.6
    • Sakaeda, T.1    Kadoyama, K.2    Okuno, Y.3
  • 45
    • 0036144815 scopus 로고    scopus 로고
    • Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism- based prediction of volume of distribution
    • Poulin, P. & Theil, F.P. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism- based prediction of volume of distribution. J. Pharm. Sci. 91, 129-156 (2002
    • (2002) J. Pharm. Sci , vol.91 , pp. 129-156
    • Poulin, P.1    Theil, F.P.2
  • 46
    • 21344469211 scopus 로고    scopus 로고
    • Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases
    • Rodgers, T., Leahy, D. & Rowland, M. Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases. J. Pharm. Sci. 94, 1259- 1276 (2005
    • (2005) J. Pharm. Sci , vol.94 , pp. 1259-1276
    • Rodgers, T.1    Leahy, D.2    Rowland, M.3
  • 47
    • 0034283671 scopus 로고    scopus 로고
    • Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: Involvement of an inhibitory G protein
    • Sadeghi, M.M., Collinge, M., Pardi, R. & Bender, J.R. Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: Involvement of an inhibitory G protein. J. Immunol. 165, 2712-2718 (2000
    • (2000) J. Immunol , vol.165 , pp. 2712-2718
    • Sadeghi, M.M.1    Collinge, M.2    Pardi, R.3    Bender, J.R.4
  • 48
    • 22544454498 scopus 로고    scopus 로고
    • Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1.*5, SLCO1B1.*15 and SLCO1B1.*15+C1007G, by using transient expression systems of HeLa and HEK293 cells
    • Kameyama, Y., Yamashita, K., Kobayashi, K., Hosokawa, M. & Chiba, K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1.*5, SLCO1B1.*15 and SLCO1B1.*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics 15, 513-522 (2005
    • (2005) Pharmacogenet. Genomics , vol.15 , pp. 513-522
    • Kameyama, Y.1    Yamashita, K.2    Kobayashi, K.3    Hosokawa, M.4    Chiba, K.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.